Vectura, the pharma company specialising in treatments for respiratory diseases, says a trial of one of its development drugs has shown better results than the main competitor.
The not-catchily titled QVA149 is a treatment delivered through an inhaler, mainly targeted at chronic obstructive pulmonary disease - a condition often seen in smokers, or people working in a polluted environment, which can cause debilitating bouts of breathlessness.
The latest study results show a once daily dose of QVA149 gives patients "superior" lung function to the twice daily treatment Seretide.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The drug will now progress to phase III trials in the US, managed by its partner in the project, pharma giant, Novartis.
Vectura shares had gained 4.35% by 10:12.
BS
-
Are UK stocks still worth buying?News UK investors are snubbing home-grown stocks, but there are opportunities - we reveal where to find unloved listed British businesses and if UK stocks are still worth buying
-
House prices are falling in London but how does it compare to the rest of the UK?
Advice The capital remains the most expensive part of the UK to buy a property, but it isn’t being as badly hit by the housing market slump. Where are London house prices heading?
